AI brings savings to clinical trials: study
TL;DR
A new analysis from the Tufts Center for the Study of Drug Development finds that AI agents can accelerate clinical development of cancer drugs by roughly ten weeks. In late stage trials that could cut direct operating costs by as much as 5.6 million dollars. The potential benefit grows with the number of tumor types a drug can target. The gains show up in patient recruitment and enrollment, trial monitoring and data interpretation.
Nauti's Take
Pharma teams should test AI first in patient recruitment and data preparation, where time savings are easiest to measure. The figures come from a single Tufts analysis first reported by Axios, so the cost estimates still need independent validation.
Before changing budgets, teams should check the assumptions around tumor types, trial size, and human oversight.
Sources